{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-013615","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.362425+00:00","generated_at":"2026-06-19T05:11:02.322450+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BiomX raises ~$7.5M in PIPE; reports positive Phase 1b/2a data for BX004 in CF","bullets":["Private placement of 30.6M shares at $0.245; gross proceeds ~$7.5M in two closings.","First closing of ~$1.5M (5.98M securities) imminent; second closing contingent on shareholder approval.","Part 1 Phase 1b/2a: BX004 reduced P. aeruginosa by -1.42 log10 CFU/g vs -0.28 placebo at Day 15.","No safety events or emerging resistance; phages detected in all treated patients during dosing.","Part 2 (24 patients) expected Q3 2023; proceeds to fund BX004 CF development and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-013615","json":"https://secwatch.observer/filing/0001213900-23-013615.json","markdown":"https://secwatch.observer/filing/0001213900-23-013615.md","text":"https://secwatch.observer/filing/0001213900-23-013615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/0001213900-23-013615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/ea174091-8k_biomxinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:11:02.322450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"308a31ff98fc1851d24798cfdcde76f338e86594","claim":"BiomX Inc. entered into Securities Purchase Agreement with accredited and non-U.S. investors valued at approximately $7.5 million gross proceeds (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, BiomX Inc. (the “ Company ”) executed a definitive Securities Purchase Agreement (the “ SPA ”) with accredited and non-U.S. investors relating to a private placement (the “ Offering ”) of an aggregate of 30,608,163 shares of the Company’s common stock (“ Shares ”), including shares issuable upon the exercise of pre-funded warrants (“ Pre-Funded Warrants ”) to purchase additional shares of the Company’s common stock (each, a “ Security ” and collectively, the “ Securities ”), at a purchase price of $0.245 per Share and $0.244 per Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/0001213900-23-013615-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited and non-U.S. investors"},{"label":"Value","value":"approximately $7.5 million gross proceeds"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}